News & Updates
Filter by Specialty:
T2DM: SGLT2 inhibitors associated with lower rates of ICU admission and all-cause mortality
A retrospective observational study of nearly 28,000 patients with type 2 diabetes mellitus (T2DM) in Hong Kong finds that use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is independently associated with lower rates of ICU admission and all-cause mortality across various disease categories.
T2DM: SGLT2 inhibitors associated with lower rates of ICU admission and all-cause mortality
07 Jun 2023
Does extended lymph node sampling increase complications?
Patients undergoing more extensive lymph node sampling during surgery for a suspected malignant paediatric renal tumour do not appear to have a higher likelihood of experiencing clinically significant complications, reveals a study.
Does extended lymph node sampling increase complications?
06 Jun 2023
Nivolumab-chemo poised to alter NSCLC treatment landscape
In the 3-year analysis of the phase III CheckMate 816 trial, neoadjuvant nivolumab plus platinum doublet chemotherapy (nivo-chemo) continued to provide durable benefit for individuals with resectable non-small-cell lung cancer (NSCLC).
Nivolumab-chemo poised to alter NSCLC treatment landscape
06 Jun 2023
Electroporation a promising way to end insulin dependency in T2D
A novel endoscopic electroporation procedure, when combined with semaglutide, can eliminate the need for insulin injections for individuals with type 2 diabetes (T2D), as shown in the results of the first-in-human EMINENT study.